| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
MYC-RIBOTAC targets the MYC internal ribosome entry site (IRES) within MYC mRNA. By binding to this specific RNA structure and simultaneously recruiting RNase L1 via its small molecule recruiter, it facilitates the targeted degradation of MYC mRNA, reducing both MYC mRNA and protein expression levels.
|
|---|---|
| ln Vitro |
In a dose-dependent and RNase L-dependent manner, MYC-RIBOTAC (0-10 μM; 48 hours) lowers the amounts of MYC mRNA and protein in HeLa cells [1]. HeLa cells and Namalwa cells exhibit anti-proliferative and apoptosis-inducing effects when exposed to MYC-RIBOTAC (0-10 μM) for 48 hours [1].
MYC-RIBOTAC reduces MYC mRNA and protein expression levels in treated cells. It induces cell apoptosis and can be used for antitumor research. The compound is composed of pre-miR-155 binder Anticancer agent 167, RNA binder NCI-B16 , and a Linker Amino-PEG4-alcohol . |
| ln Vivo |
Not available. As a RIBOTAC targeting MYC, its in vivo activity would be evaluated in tumor xenograft mouse models, where one would measure MYC mRNA and protein knockdown in tumor tissues, tumor growth inhibition, and assessment of apoptosis markers. Specific in vivo efficacy data is not provided in the literature.
|
| Enzyme Assay |
Not applicable. MYC-RIBOTAC does not target a protein receptor; it targets RNA. Standard methods for assessing target engagement involve RNA pull-down assays using biotinylated MYC RNA probes from cells treated with the compound, followed by Western blotting for RNase L recruitment, or RT-qPCR to quantify MYC mRNA levels.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: HeLa cells and Namalwa cells Tested Concentrations: 0-10 μM Incubation Duration: 48 hrs (hours) Experimental Results: Had antiproliferative and induce-apoptotic effects in in HeLa cells. Induced cell cycle arrest and provoked apoptosis and decreased colony formation by about 50% in Namalwa cells. Western Blot Analysis[1] Cell Types: HeLa cells Tested Concentrations: 0-10 μM Incubation Duration: 48 hrs (hours) Experimental Results: diminished the abundance of MYC mRNA in HeLa cells in a dose-dependent and RNase L dependent manner, up to around 50% at a 10 μM dose with a concomitant reduction in MYC protein levels. A standard cellular protocol for assessing MYC-RIBOTAC activity involves treating MYC-driven cancer cells (e.g., Burkitt's lymphoma or neuroblastoma cell lines) with varying concentrations of MYC-RIBOTAC (0.01-10 microM) for 24-72 hours. After treatment, cells are harvested, MYC mRNA is quantified by RT-qPCR, MYC protein levels are assessed by Western blotting, and apoptosis is measured by flow cytometry using Annexin V/PI staining. |
| Animal Protocol |
Not available. For in vivo evaluation, standard protocols would involve administering MYC-RIBOTAC to mice bearing MYC-driven tumor xenografts, typically by intratumoral or intravenous injection (e.g., 5-20 mg/kg), every 2-3 days for 2-4 weeks. Tumor volume is measured, and at endpoint, tumors are excised for analysis of MYC mRNA and protein knockdown.
|
| ADME/Pharmacokinetics |
MYC-RIBOTAC has a molecular weight of 1067.17 (C55H58N10O11S) and purity of 98.17%. For in vitro use, it is soluble in DMSO to prepare stock solutions. For in vivo formulation, standard co-solvent systems (e.g., 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline) can be used.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for MYC-RIBOTAC is not available. As a RIBOTAC targeting a critical oncogene, its toxicity profile would depend on target engagement and off-target effects. Related PROTAC/RIBOTAC molecules generally exhibit manageable toxicity in vitro at effective concentrations (0.1-10 microM), but extensive safety studies have not been published.
|
| References | |
| Additional Infomation |
MYC-RIBOTAC is a research-grade RIBOTAC tool for studying MYC-driven cancers. MYC is a well-validated but historically undruggable oncogene involved in various malignancies. This compound offers a novel approach to targeting MYC through RNA degradation rather than protein inhibition. It has not been approved for clinical use and is strictly for laboratory research in targeted RNA degradation and oncology.
|
| Molecular Formula |
C55H58N10O11S
|
|---|---|
| Molecular Weight |
1067.17
|
| Appearance |
Light yellow to yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~93.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9371 mL | 4.6853 mL | 9.3706 mL | |
| 5 mM | 0.1874 mL | 0.9371 mL | 1.8741 mL | |
| 10 mM | 0.0937 mL | 0.4685 mL | 0.9371 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
